American Well (AMWL)
Market Price (9/20/2026): $13.78 | Market Cap: $231.0 MilSector: Health Care | Industry: Health Care Technology
American Well (AMWL)
Market Price (9/20/2026): $13.78Market Cap: $231.0 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -84% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. | Trading close to highsDist 52W High is -0.9% Weak multi-year price returns3Y Excs Rtn is -120% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -81 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -37% Stock price has recently run up significantly6M Rtn6 month market price return is 140%, 12M Rtn12 month market price return is 114% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -19%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -6.8%, Rev Chg QQuarterly Revenue Change % is -27% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -15% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 187% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38% Key risksAMWL key risks include [1] a high probability of bankruptcy driven by a history of substantial net losses and [2] significant client concentration, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -84% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. |
| Trading close to highsDist 52W High is -0.9% |
| Weak multi-year price returns3Y Excs Rtn is -120% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -81 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -37% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 140%, 12M Rtn12 month market price return is 114% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -19%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -6.8%, Rev Chg QQuarterly Revenue Change % is -27% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -15% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 187% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38% |
| Key risksAMWL key risks include [1] a high probability of bankruptcy driven by a history of substantial net losses and [2] significant client concentration, Show more. |
Qualitative Assessment
AI Analysis | Feedback
American Well (AMWL) stock has gained about 40% since 5/31/2026 because of the following key factors:
1. Better-than-expected fiscal Q2 2026 financial results and improved full-year guidance.
American Well reported its fiscal second-quarter 2026 results on August 4, 2026, with revenue of $52.0 million, reaching the top end of its guidance range and exceeding analyst expectations of $49.87 million. The company demonstrated improved profitability metrics, with a net loss narrowing to ($9.6) million from ($10.3) million in fiscal Q1 2026, and an adjusted EBITDA loss shrinking to ($1.2) million from ($3.1) million in fiscal Q1 2026. Furthermore, Amwell achieved positive operating cash flow of $9.7 million in the first half of 2026, a significant improvement from the $29.8 million used in the first half of 2025. Following these results, Amwell raised its full-year 2026 revenue guidance to a range of $200-$205 million, up from the previous $195-$205 million, and improved its adjusted EBITDA guidance to a loss of $9-$7 million, from a prior range of $16-$12 million. The company also reaffirmed its objective to achieve positive cash flow from operations in fiscal Q4 2026.
2. Significant Letter of Intent from the Department of Veterans Affairs.
On September 8, 2026, American Well announced it had received a Letter of Intent from the Department of Veterans Affairs (VA) to help power its digital health infrastructure. This development is a strong endorsement of Amwell's platform and signifies a major potential government contract, highlighting the company's growing traction in the public sector.
Show more
American Well (AMWL) stock has gained about 40% since 5/31/2026 because of the following key factors:
1. Better-than-expected fiscal Q2 2026 financial results and improved full-year guidance.
American Well reported its fiscal second-quarter 2026 results on August 4, 2026, with revenue of $52.0 million, reaching the top end of its guidance range and exceeding analyst expectations of $49.87 million. The company demonstrated improved profitability metrics, with a net loss narrowing to ($9.6) million from ($10.3) million in fiscal Q1 2026, and an adjusted EBITDA loss shrinking to ($1.2) million from ($3.1) million in fiscal Q1 2026. Furthermore, Amwell achieved positive operating cash flow of $9.7 million in the first half of 2026, a significant improvement from the $29.8 million used in the first half of 2025. Following these results, Amwell raised its full-year 2026 revenue guidance to a range of $200-$205 million, up from the previous $195-$205 million, and improved its adjusted EBITDA guidance to a loss of $9-$7 million, from a prior range of $16-$12 million. The company also reaffirmed its objective to achieve positive cash flow from operations in fiscal Q4 2026.
2. Significant Letter of Intent from the Department of Veterans Affairs.
On September 8, 2026, American Well announced it had received a Letter of Intent from the Department of Veterans Affairs (VA) to help power its digital health infrastructure. This development is a strong endorsement of Amwell's platform and signifies a major potential government contract, highlighting the company's growing traction in the public sector.
3. Strategic pivot towards government and commercial payers, coupled with industry recognition for its technology platform.
Amwell's management, including COO Mark Hirschhorn, outlined a refined strategy at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, emphasizing a focus on government agencies and commercial payers. The company is transitioning from a broad, customized development model to a focused platform company, aiming for more recurring, platform-based subscription revenue, which is now approaching half of its total revenue. Further validating this strategic direction, Amwell received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry on September 3, 2026. This recognition acknowledged Amwell's unified platform for addressing healthcare fragmentation by orchestrating consumer experiences, clinician workflows, care programs, and partner solutions.
Show less
Stock Movement Drivers
Fundamental Drivers
The 39.9% change in AMWL stock from 5/31/2026 to 9/19/2026 was primarily driven by a 53.5% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9192026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.83 | 13.75 | 39.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 237 | 219 | -7.9% |
| P/S Multiple | 0.7 | 1.1 | 53.5% |
| Shares Outstanding (Mil) | 17 | 17 | -1.0% |
| Cumulative Contribution | 39.9% |
Market Drivers
5/31/2026 to 9/19/2026| Return | Correlation | |
|---|---|---|
| AMWL | 39.9% | |
| Market (SPY) | 0.9% | 4.2% |
| Sector (XLV) | 12.7% | 21.4% |
Fundamental Drivers
The 141.2% change in AMWL stock from 2/28/2026 to 9/19/2026 was primarily driven by a 181.2% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9192026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.70 | 13.75 | 141.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 249 | 219 | -12.4% |
| P/S Multiple | 0.4 | 1.1 | 181.2% |
| Shares Outstanding (Mil) | 16 | 17 | -2.1% |
| Cumulative Contribution | 141.2% |
Market Drivers
2/28/2026 to 9/19/2026| Return | Correlation | |
|---|---|---|
| AMWL | 141.2% | |
| Market (SPY) | 11.6% | 14.9% |
| Sector (XLV) | 5.5% | 19.2% |
Fundamental Drivers
The 99.3% change in AMWL stock from 8/31/2025 to 9/19/2026 was primarily driven by a 159.5% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9192026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.90 | 13.75 | 99.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 270 | 219 | -19.0% |
| P/S Multiple | 0.4 | 1.1 | 159.5% |
| Shares Outstanding (Mil) | 16 | 17 | -5.2% |
| Cumulative Contribution | 99.3% |
Market Drivers
8/31/2025 to 9/19/2026| Return | Correlation | |
|---|---|---|
| AMWL | 99.3% | |
| Market (SPY) | 19.4% | 17.9% |
| Sector (XLV) | 24.1% | 19.8% |
Fundamental Drivers
The -51.6% change in AMWL stock from 8/31/2023 to 9/19/2026 was primarily driven by a -27.9% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9192026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.40 | 13.75 | -51.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 275 | 219 | -20.5% |
| P/S Multiple | 1.5 | 1.1 | -27.9% |
| Shares Outstanding (Mil) | 14 | 17 | -15.5% |
| Cumulative Contribution | -51.6% |
Market Drivers
8/31/2023 to 9/19/2026| Return | Correlation | |
|---|---|---|
| AMWL | -51.6% | |
| Market (SPY) | 75.6% | 24.0% |
| Sector (XLV) | 32.3% | 26.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AMWL Return | -76% | -53% | -47% | -76% | -32% | 178% | -97% |
| Peers Return | -31% | -43% | 6% | 36% | -16% | -16% | -60% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| AMWL Win Rate | 17% | 33% | 42% | 42% | 25% | 67% | |
| Peers Win Rate | 35% | 37% | 50% | 47% | 37% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| AMWL Max Drawdown | -87% | -58% | -77% | -83% | -70% | -21% | |
| Peers Max Drawdown | -62% | -69% | -55% | -47% | -53% | -51% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, HIMS, DOCS, GDRX, PHR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | AMWL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -50.4% | -18.8% |
| % Gain to Breakeven | 101.8% | 23.1% |
| Time to Breakeven | 442 days | 79 days |
In The Past
American Well's stock fell -50.4% during the 2025 US Tariff Shock. Such a loss loss requires a 101.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AMWL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -50.4% | -18.8% |
| % Gain to Breakeven | 101.8% | 23.1% |
| Time to Breakeven | 442 days | 79 days |
In The Past
American Well's stock fell -50.4% during the 2025 US Tariff Shock. Such a loss loss requires a 101.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About American Well (AMWL)
American Well (AMWL) operates as a leading telehealth software company, providing the essential technology infrastructure for the digital delivery of healthcare services. Its core business revolves around enabling healthcare providers to offer a wide spectrum of care remotely, making medical consultations and treatments more accessible to patients.
The company's offerings include a robust application platform that supports diverse medical needs, such as urgent care, scheduled visits, pediatrics, behavioral health therapy, and specialized treatments for conditions like telestroke, menopause nutrition, and end-stage renal disease. Beyond software, American Well also supplies crucial telemedicine equipment, including specialized carts, peripherals, TV kits, tablets, and kiosks, which further facilitate remote care delivery in various settings.
American Well's solutions are designed to serve the broader healthcare industry, empowering providers to extend their reach into various environments. This includes traditional clinical settings, retail health clinics, schools, and patients' homes, effectively transforming how healthcare is delivered and accessed across different patient populations and geographical locations.
AI Analysis | Feedback
Here are 1-3 brief analogies for American Well (AMWL):
- Shopify for virtual healthcare.
- Zoom for doctor visits.
AI Analysis | Feedback
- Telehealth Software Platform: A comprehensive software platform that facilitates the digital delivery of various healthcare services.
- Digital Care Services: A broad spectrum of virtual medical services covering areas such as urgent care, pediatrics, therapy, behavioral health, telestroke, and specialized chronic care management.
- Telemedicine Equipment: Physical hardware components including telemedicine carts, peripherals, TV kits, tablets, and kiosks that support virtual care delivery.
AI Analysis | Feedback
American Well (AMWL) primarily sells its telehealth software and equipment to other companies in the healthcare ecosystem. Its major customers fall into the following categories:
- Health Plans/Payers: Large health insurance companies that integrate Amwell's platform to offer telehealth services to their members. A prominent example includes Elevance Health (NYSE: ELV), formerly known as Anthem.
- Health Systems and Hospitals: Large hospital networks, integrated delivery systems, and physician groups that utilize Amwell's technology to provide virtual care to their patient populations. Examples include major systems like Intermountain Healthcare and Cleveland Clinic, which are typically private or non-profit entities without public stock symbols.
- Large Employers: Companies that partner with Amwell to offer comprehensive telehealth services as a benefit to their employees.
AI Analysis | Feedback
- Amazon.com, Inc. (AMZN)
- Microsoft Corporation (MSFT)
AI Analysis | Feedback
Ido Schoenberg, Chairman and CEO
Ido Schoenberg co-founded American Well (Amwell) with his brother Roy in 2006, guiding its strategic direction to become a prominent digital care enablement company. He has a history of successfully leading healthcare technology firms, including co-founding iMDSoft in 1996, which developed enterprise software for hospital critical care units. He also served as CEO of CareKey Inc., overseeing its acquisition by the TriZetto group, where he then became Chief Business Strategy Officer until 2006. Dr. Schoenberg holds an M.D. from the Sackler School of Medicine.
Robert Shepardson, Chief Financial Officer
Robert Shepardson joined Amwell from Morgan Stanley, where he held various leadership positions, including Managing Director in Global Capital Markets responsible for equity issuance in the Healthcare vertical. He led financings for numerous high-growth healthcare companies. Mr. Shepardson also serves on the board of The Alliance for Positive Change. He holds a Bachelor of Arts in Economics from Princeton University and an MBA from the Tuck School of Business at Dartmouth College.
Roy Schoenberg, Executive Vice Chairman
Roy Schoenberg co-founded Amwell with his brother Ido in 2006. He previously served as President and co-CEO until June 2024, when he transitioned to Executive Vice Chairman. Prior to Amwell, he founded CareKey and became Chief Information Security Officer at TriZetto after its acquisition. Dr. Schoenberg holds over 50 U.S.-issued patents in healthcare technology and serves on advisory boards for the MIT Sloan Health Initiative, Brigham and Women's Hospital Center for Patient Safety Research and Practice, and the American Heart Association Telehealth board. He earned his M.D. from The Hebrew University and an M.P.H. from Harvard.
Serkan Kutan, Chief Technology Officer
Serkan Kutan is responsible for leading the development and scaling of Amwell's telehealth platform. Before joining Amwell, he was the Chief Technology Officer at Haven, a joint venture formed by Amazon, Berkshire Hathaway, and JPMorgan Chase, where he focused on driving innovation and building a data platform. Mr. Kutan also served as CTO for Zocdoc, where he oversaw the transformation of its technology stack, migration to Amazon Web Services, and reorganization of product engineering. His career includes key technology leadership roles at Amazon, Goldman Sachs, and Microsoft. He holds a Bachelor's in Computer Science from Bilkent University.
Kurt Knight, Chief Operating Officer
Kurt Knight oversees Amwell's business and operational aspects, bringing extensive experience in healthcare. His background includes work at the Boston Consulting Group, where he focused on pharma and global health, and at Hill-Rom, where he established a new home care business. He has also addressed global health challenges with organizations such as the Gates Foundation, Save the Children, and Unicef. Mr. Knight holds an MPH from Columbia University and an MBA from Harvard.
AI Analysis | Feedback
Here are the key risks to American Well (AMWL):
- Execution Risk of Converge Platform Migration and Client Churn: American Well's strategy is centered on migrating its substantial client base of health systems and health plans to its unified Converge platform. This transition is a complex undertaking, and there is a significant risk of client churn if the migration process proves too complicated or costly, or if integration with clients' existing Electronic Health Record (EHR) systems is problematic. The slow pace of client migration is a notable challenge.
- Intense Competition and Market Pressure: The enterprise telehealth platform market is highly competitive. American Well faces pressure from well-funded competitors, including major players like Teladoc Health, which has expanded its reach through collaborations with entities like Amazon's Health Benefits Connector. The market is also evolving, with some companies, such as Optum and Walmart, exiting certain virtual care services, indicating a challenging and dynamic environment where pricing and market share are key concerns.
- Financial Challenges: American Well has a history of incurring significant net losses and is projected to continue doing so in the near term. The company's revenue growth has been slow or, at times, declining. While the company maintains some liquidity, financial analyses indicate its Altman Z-Score places it in a distress zone, suggesting a potential risk of bankruptcy. The company aims to achieve positive cash flow from operations by the fourth quarter of 2026, but continued losses and slow growth present ongoing financial risks.
AI Analysis | Feedback
The clear emerging threat is the intensified entry of large technology companies, such as Amazon, into direct telehealth service provision and the potential offering of integrated telehealth platforms. These companies leverage vast ecosystems, consumer reach, and significant technological resources, which could disrupt the market for dedicated telehealth software and equipment providers like American Well by setting new standards for platform integration, consumer experience, and cost-effectiveness, or by developing proprietary platforms that reduce reliance on third-party solutions.
AI Analysis | Feedback
American Well Corporation (AMWL) operates in several significant addressable markets related to telehealth and digital healthcare. The main products and services offered by the company, including urgent care, scheduled visits, acute behavioral health, chronic disease management, and telemedicine equipment, fall within these growing markets.
Addressable Markets for American Well (AMWL)
-
Overall Telehealth and Virtual Care Market:
- The global telehealth market was estimated at approximately USD 210 billion in 2025 and is projected to exceed USD 2 trillion by 2034. Other estimates place the global market at USD 186.41 billion in 2025, growing to USD 1,272.81 billion by 2034.
- In the U.S., the telehealth market was valued at USD 78.25 billion in 2025 and is projected to reach around USD 678.50 billion by 2035. Another report indicates a U.S. telehealth market size of USD 94.3 billion in 2025, growing to USD 395.6 billion by 2034.
- North America is identified as the largest telehealth market globally.
- The U.S. virtual care market was estimated at USD 8.83 billion in 2024 and is expected to grow to USD 48.54 billion by 2034. Another source projects the U.S. virtual care market to reach approximately USD 51.2 billion by 2030.
-
Behavioral and Mental Health Telehealth Market:
- The global telehealth services market for behavioral and mental health was estimated at USD 3.23 billion in 2023 and is expected to grow to USD 8.5 billion by 2032.
- American Well itself identified the U.S. digital behavioral health market as a USD 29 billion opportunity within its roughly USD 77 billion total addressable market in 2022.
- Amwell also estimated the total addressable market in international behavioral health to be about USD 52 billion.
- The mental health & behavioral therapy segment is anticipated to experience the fastest growth within the U.S. telehealth market.
-
Remote Patient Monitoring (RPM) Market:
- The global remote patient monitoring market was valued at USD 39.97 billion in 2025 and is expected to reach USD 103.95 billion by 2033. Another report projects the global RPM market to reach US$ 117.9 billion by 2033.
- The U.S. remote patient monitoring market size was valued at USD 14.33 billion in 2024 and is expected to reach USD 36.25 billion by 2033. Other estimates for the U.S. RPM market include USD 14.15 billion in 2024, growing to USD 29.13 billion by 2030.
-
Chronic Disease Management (CDM) Market:
- The global chronic disease management market was valued at USD 4.83 billion in 2023 and is projected to reach USD 15.58 billion by 2032.
- The U.S. chronic disease management market was valued at USD 1.8 billion in 2025 and is projected to reach USD 5.0 billion by 2034. Another estimate for the U.S. market is USD 2.6 billion in 2025, reaching USD 8.2 billion by 2034.
-
Urgent Care Market (U.S.):
- The U.S. Urgent Care Centers Market was valued at USD 34.34 billion in 2024 and is projected to reach USD 55.07 billion by 2030.
- Telehealth adoption is a key factor propelling the growth of the urgent care market.
-
Acute Care Telemedicine Market (U.S.):
- The USA Acute Care Telemedicine Market is valued at approximately USD 10 billion.
-
Telemedicine Equipment Market:
- Within the broader telehealth market, the "products segment" (which includes hardware like telemedicine equipment) is expected to grow. In 2025, the products segment dominated the U.S. telemedicine market.
AI Analysis | Feedback
American Well (AMWL) anticipates future revenue growth over the next 2-3 years to be driven by several key strategic initiatives and market expansions:
- Shift to a SaaS-based Subscription Model: American Well is undergoing a strategic transition from lower-margin, volume-based visit revenue to a more predictable, high-margin Software-as-a-Service (SaaS) subscription model. This shift is projected to constitute nearly 60% of its total revenue by 2025. This strategic move is designed to enhance profitability and is expected to contribute to positive cash flow from operations by the end of 2026.
- Expansion and Adoption of the Converge Platform: A significant driver is the ongoing transition of major clients, including large health plans like Florida Blue, to the comprehensive Converge platform for unified digital care. The Converge platform is engineered to digitally enable hybrid care across all settings for payers and health systems, incorporating services such as virtual primary care, urgent care, and specialized clinical programs. The company's strategic focus on its Technology Enabled Care platform is tailored to address the evolving needs of government, payer, and health system clients by integrating Amwell's clinical programs with advanced AI-driven, third-party clinical applications.
- Integration of AI and Automation: The company is heavily investing in technology and AI integration, which is expected to drive efficiencies and enhance its platform offerings. Amwell's CEO has emphasized building an enterprise-grade platform underpinned by AI integration, leveraging investments in interoperability and data exchange to position Amwell as a dependable, secure, and scalable technology-enabled care platform. These AI-driven efficiencies and integrations are anticipated to help clients reduce costs, improve outcomes, and transform patient care.
- Growth in Strategic Client Contracts and Renewals: A key area of focus for revenue growth includes expanding its footprint in the government market and securing renewals with major payers and health systems. Amwell has successfully executed over 15 payer contract renewals, including a three-year renewal with Elevance, and brought Blue Cross Blue Shield of Florida online, bolstering recurring revenue stability. The company is also progressing with its government contracts, including staged go-lives across the Military Health System.
- Expansion of Virtual Primary and Specialty Care Programs: Increased visit volumes in specialty care and virtual primary care are identified as a growth driver. The Amwell Medical Group (AMG) has seen an increase in average revenue per visit, influenced by a strategic shift towards virtual primary care and various specialty programs. Amwell's platform facilitates comprehensive care delivery, spanning from primary and urgent care to highly specialized consultations such as telepsychiatry, and has recently expanded its offerings with a cardiometabolic program through a partnership.
AI Analysis | Feedback
Capital Allocation Decisions for American Well (AMWL)
Share Issuance
- American Well implemented a 0.05:1 reverse stock split on July 10, 2024.
Outbound Investments
- In 2021, American Well acquired Conversa Health, Inc. and SilverCloud Health Holdings, Inc., expanding its capabilities in automated care and behavioral health.
- In January 2025, Amwell divested its telepsychiatry services business to Avel eCare, LLC, receiving an upfront payment of $20.7 million. This divestiture resulted in an $8.7 million gain recognized during the first nine months of 2025.
- American Well and Cleveland Clinic agreed to liquidate their CCAW joint venture, with remaining transition activities anticipated to conclude by March 31, 2026.
Capital Expenditures
- American Well anticipates that its existing cash and cash equivalents will be sufficient to cover working capital and capital expenditure needs for at least the next 12 months.
- The company plans to focus on long-term revenue growth through continued investments in technology and strategic customer relationships.
Peer Outperformance in Health Care Technology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.6% | 89.3% | CAH 387% · MCK 344% · COR 167% |
| Health Care Services | 20 | 21.1% | 38.6% | 1.2% | HIMS 248% · RDNT 176% · DGX 76% |
| Managed Health Care | 8 | 40.4% | -3.7% | 0.8% | OSCR 87% · HQY 54% · ELV 17% |
| Health Care Facilities | 24 | 6.0% | 4.6% | -9.2% | NHC 272% · THC 265% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -3.3% | -20.5% | POCI 11050% · UFPT 344% · GKOS 216% |
| Pharmaceuticals | 62 | -10.5% | 14.7% | -38.8% | LQDA 2512% · INDV 1092% · ETON 1040% |
| Health Care Supplies | 12 | 14.1% | -11.1% | -40.0% | LNTH 290% · HAE 57% · MMSI 19% |
| Life Sciences Tools & Services | 109 | 4.3% | -12.6% | -67.5% | SNWV 1757% · MEDP 235% · NTRA 209% |
| Health Care Technology ← | 21 | -25.8% | -52.4% | -79.1% | SPOK 69% · HSTM 3% · VEEV -12% |
| Biotechnology | 364 | 0.6% | -21.4% | -79.3% | CELZ 1280% · DNTH 1217% · ELVN 1080% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| American Well Earnings Notes | 12/16/2025 | |
| Is American Well Stock Built to Withstand a Pullback? | 10/17/2025 | |
| ARTICLES | ||
| What’s Next For Amwell After 55% Growth From IPO Price? | 10/05/2020 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 11.89 |
| Mkt Cap | 1.1 |
| Rev LTM | 720 |
| Op Inc LTM | -34 |
| FCF LTM | 93 |
| FCF 3Y Avg | 97 |
| CFO LTM | 231 |
| CFO 3Y Avg | 195 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 8.2% |
| Rev Chg Q | 3.0% |
| QoQ Delta Rev Chg LTM | 0.7% |
| Op Inc Chg LTM | 2.5% |
| Op Inc Chg 3Y Avg | 32.1% |
| Op Mgn LTM | -1.7% |
| Op Mgn 3Y Avg | -3.3% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 14.2% |
| CFO/Rev 3Y Avg | 11.7% |
| FCF/Rev LTM | 9.0% |
| FCF/Rev 3Y Avg | 5.8% |
Price Behavior
| Market Price | $13.75 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 09/17/2020 | |
| Distance from 52W High | -0.9% | |
| 50 Days | 200 Days | |
| DMA Price | $12.15 | $7.63 |
| DMA Trend | up | up |
| Distance from DMA | 13.1% | 80.2% |
| 3M | 1YR | |
| Volatility | 86.7% | 71.2% |
| Downside Capture | -117.13 | 47.40 |
| Upside Capture | 155.59 | 128.79 |
| Correlation (SPY) | -1.9% | 18.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.29 | -0.23 | 0.06 | 0.79 | 0.99 | 1.32 |
| Up Beta | -1.48 | -1.11 | 0.37 | 1.40 | 0.95 | 1.49 |
| Down Beta | 10.63 | -0.72 | 0.34 | 1.31 | 1.56 | 1.01 |
| Up Capture | 32% | 143% | 40% | 127% | 108% | 116% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 21 | 29 | 64 | 122 | 347 |
| Down Capture | -248% | -71% | -62% | -57% | 60% | 110% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 21 | 35 | 63 | 126 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AMWL | |
|---|---|---|---|---|
| AMWL | 112.5% | 70.9% | 1.34 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 19.2% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 18.5% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 10.8% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -5.4% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 19.1% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AMWL | |
|---|---|---|---|---|
| AMWL | -41.8% | 78.5% | -0.36 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 29.3% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 32.8% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 8.1% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | 1.9% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 37.2% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | 18.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AMWL | |
|---|---|---|---|---|
| AMWL | -29.3% | 78.6% | -0.40 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 25.3% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 28.5% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 7.0% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 3.9% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 30.0% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | 13.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/4/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | 25.0% | 24.7% | 23.1% |
| 5/5/2026 | 12.4% | 24.1% | 38.1% |
| 2/12/2026 | 24.7% | 25.9% | 30.0% |
| 11/4/2025 | -9.5% | -22.8% | -20.6% |
| 8/5/2025 | -7.3% | -16.7% | -20.8% |
| 5/1/2025 | 19.7% | 12.4% | 6.3% |
| 2/12/2025 | -5.0% | -2.3% | -35.5% |
| 10/30/2024 | -5.1% | -7.7% | -0.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 12 |
| # Negative | 15 | 15 | 12 |
| Median Positive | 18.0% | 12.4% | 12.2% |
| Median Negative | -5.1% | -8.0% | -20.2% |
| Max Positive | 40.2% | 25.9% | 48.7% |
| Max Negative | -21.6% | -23.8% | -38.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | 25.0% | 24.7% | 23.1% |
| 5/5/2026 | 12.4% | 24.1% | 38.1% |
| 2/12/2026 | 24.7% | 25.9% | 30.0% |
| 11/4/2025 | -9.5% | -22.8% | -20.6% |
| 8/5/2025 | -7.3% | -16.7% | -20.8% |
| 5/1/2025 | 19.7% | 12.4% | 6.3% |
| 2/12/2025 | -5.0% | -2.3% | -35.5% |
| 10/30/2024 | -5.1% | -7.7% | -0.8% |
| 7/31/2024 | 40.2% | -0.9% | 2.0% |
| 5/1/2024 | -2.1% | -2.5% | -19.6% |
| 2/14/2024 | 18.0% | -2.7% | -19.8% |
| 11/1/2023 | 13.6% | 4.2% | 10.2% |
| 8/2/2023 | -5.0% | -21.2% | -36.0% |
| 5/3/2023 | -6.1% | 0.0% | 15.1% |
| 2/22/2023 | -13.8% | -23.8% | -38.1% |
| 11/7/2022 | -3.8% | 11.4% | -9.8% |
| 8/4/2022 | 7.5% | 8.0% | -6.2% |
| 5/9/2022 | -3.7% | 13.2% | 48.7% |
| 2/24/2022 | -0.7% | -9.6% | -14.8% |
| 11/10/2021 | -6.2% | -9.4% | -28.7% |
| 8/11/2021 | 4.6% | -1.6% | 4.8% |
| 5/12/2021 | -21.6% | -8.0% | 8.6% |
| 3/24/2021 | -1.6% | -6.3% | 1.0% |
| 11/12/2020 | -18.0% | -18.1% | 14.3% |
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 12 |
| # Negative | 15 | 15 | 12 |
| Median Positive | 18.0% | 12.4% | 12.2% |
| Median Negative | -5.1% | -8.0% | -20.2% |
| Max Positive | 40.2% | 25.9% | 48.7% |
| Max Negative | -21.6% | -23.8% | -38.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/12/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/01/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/12/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/01/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 03/26/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 09/18/2020 | 424B4 |
Recent Forward Guidance
Updated 8/5/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Revenue | Reported | 46.00 Mil | 47.00 Mil | 48.00 Mil | -6.0% | Lower New | Guidance: 50.00 Mil for Q2 2026 | |
| Q3 2026 Adjusted EBITDA | Reported | -5.00 Mil | -4.00 Mil | -3.00 Mil | Lower New | Guidance: -3.00 Mil for Q2 2026 | ||
| 2026 AMG Visits | Reported | 1.32 Mil | 1.34 Mil | 1.37 Mil | 0 | Affirmed | Guidance: 1.34 Mil for 2026 | |
| 2026 Revenue | Reported | 200.00 Mil | 202.50 Mil | 205.00 Mil | 1.2% | Raised | Guidance: 200.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | -9.00 Mil | -8.00 Mil | -7.00 Mil | Raised | Guidance: -14.00 Mil for 2026 | ||
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | Reported | 48.00 Mil | 50.00 Mil | 52.00 Mil | -1.0% | Lower New | Guidance: 50.50 Mil for Q1 2026 | |
| Q2 2026 Adjusted EBITDA | Reported | -4.00 Mil | -3.00 Mil | -2.00 Mil | -50.0% | Higher New | Guidance: -6.00 Mil for Q1 2026 | |
| 2026 AMG visits | Reported | 1.32 Mil | 1.34 Mil | 1.37 Mil | 0 | Affirmed | Guidance: 1.34 Mil for 2026 | |
| 2026 Revenue | Reported | 195.00 Mil | 200.00 Mil | 205.00 Mil | 0 | Affirmed | Guidance: 200.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | -16.00 Mil | -14.00 Mil | -12.00 Mil | -33.3% | Raised | Guidance: -21.00 Mil for 2026 | |
Q4 2025 Earnings Reported 2/12/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 48.00 Mil | 50.50 Mil | 53.00 Mil | -3.8% | Lower New | Actual: 52.50 Mil for Q4 2025 | |
| Q1 2026 Adjusted EBITDA | Reported | -7.00 Mil | -6.00 Mil | -5.00 Mil | -55.6% | Higher New | Actual: -13.50 Mil for Q4 2025 | |
| 2026 AMG visits | Reported | 1.32 Mil | 1.34 Mil | 1.37 Mil | 1.5% | Higher New | Actual: 1.32 Mil for 2025 | |
| 2026 Revenue | Reported | 195.00 Mil | 200.00 Mil | 205.00 Mil | -18.9% | Lower New | Actual: 246.50 Mil for 2025 | |
| 2026 Adjusted EBITDA | Reported | -24.00 Mil | -21.00 Mil | -18.00 Mil | 51.7% | Higher New | Actual: -43.50 Mil for 2025 | |
Q3 2025 Earnings Reported 11/4/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue | Reported | 51.00 Mil | 52.50 Mil | 54.00 Mil | ||||
| Q4 2025 Adjusted EBITDA | Reported | -15.00 Mil | -13.50 Mil | -12.00 Mil | ||||
| 2025 AMG Visits | Reported | 1.30 Mil | 1.32 Mil | 1.35 Mil | 0 | Affirmed | Guidance: 1.32 Mil for 2025 | |
| 2025 Revenue | Reported | 245.00 Mil | 246.50 Mil | 248.00 Mil | -0.4% | Lowered | Guidance: 247.50 Mil for 2025 | |
| 2025 Adjusted EBITDA | Reported | -45.00 Mil | -43.50 Mil | -42.00 Mil | 8.4% | Raised | Guidance: -47.50 Mil for 2025 | |
Insider Activity
Updated 9/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hirschhorn, Mark | Chief Financial Officer | Direct | Sell | 9032026 | 11.80 | 10,751 | 126,862 | 2,692,618 | Form |
| 2 | Gotlib, Phyllis | President, International | Direct | Sell | 9032026 | 11.80 | 3,573 | 42,161 | 1,760,336 | Form |
| 3 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 9032026 | 11.80 | 112 | 1,322 | 114,920 | Form |
| 4 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 7012026 | 9.33 | 653 | 6,092 | 91,910 | Form |
| 5 | Hirschhorn, Mark | Chief Financial Officer | Direct | Sell | 7012026 | 9.33 | 4,299 | 40,110 | 2,229,301 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hirschhorn, Mark | Chief Financial Officer | Direct | Sell | 9032026 | 11.80 | 10,751 | 126,862 | 2,692,618 | Form |
| 2 | Gotlib, Phyllis | President, International | Direct | Sell | 9032026 | 11.80 | 3,573 | 42,161 | 1,760,336 | Form |
| 3 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 9032026 | 11.80 | 112 | 1,322 | 114,920 | Form |
| 4 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 7012026 | 9.33 | 653 | 6,092 | 91,910 | Form |
| 5 | Hirschhorn, Mark | Chief Financial Officer | Direct | Sell | 7012026 | 9.33 | 4,299 | 40,110 | 2,229,301 | Form |
| 6 | Zamansky, Dmitry | Chief Product & Tech. Officer | Direct | Sell | 7012026 | 9.33 | 8,460 | 78,932 | 2,170,345 | Form |
| 7 | Gotlib, Phyllis | President, International | Direct | Sell | 7012026 | 9.33 | 6,677 | 62,296 | 1,425,195 | Form |
| 8 | Schlegel, Stephen J | Direct | Sell | 6152026 | 8.76 | 9,750 | 85,449 | 478,102 | Form | |
| 9 | Hirschhorn, Mark | Chief Financial Officer | Direct | Sell | 6032026 | 9.74 | 10,761 | 104,812 | 2,369,138 | Form |
| 10 | Gotlib, Phyllis | President, International | Direct | Sell | 6032026 | 9.74 | 3,573 | 34,801 | 1,552,858 | Form |
| 11 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 6032026 | 9.74 | 112 | 1,091 | 102,309 | Form |
| 12 | Schoenberg, Ido | Chairman, co-CEO | Direct | Buy | 5112026 | 7.37 | 670 | 4,938 | 846,960 | Form |
| 13 | Gotlib, Phyllis | President, International | Direct | Sell | 4022026 | 5.30 | 3,706 | 19,642 | 863,921 | Form |
| 14 | Zamansky, Dmitry | Chief Product & Tech. Officer | Direct | Sell | 4022026 | 5.30 | 5,575 | 29,548 | 1,277,724 | Form |
| 15 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 4022026 | 5.30 | 383 | 2,030 | 56,265 | Form |
| 16 | Zamansky, Dmitry | Chief Product & Tech. Officer | Direct | Sell | 3032026 | 5.45 | 2,472 | 13,472 | 1,069,519 | Form |
| 17 | Hirschhorn, Mark | Chief Financial Officer | Direct | Sell | 3032026 | 5.24 | 10,796 | 56,571 | 1,066,791 | Form |
| 18 | Gotlib, Phyllis | President, International | Direct | Sell | 3032026 | 5.24 | 3,573 | 18,723 | 609,396 | Form |
| 19 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 3032026 | 5.24 | 130 | 681 | 15,369 | Form |
| 20 | Zamansky, Dmitry | Chief Product & Tech. Officer | Direct | Sell | 1052026 | 4.85 | 6,243 | 30,279 | 928,620 | Form |
| 21 | Gotlib, Phyllis | President, International | Direct | Sell | 1052026 | 4.85 | 3,707 | 17,979 | 581,370 | Form |
| 22 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 1052026 | 4.85 | 384 | 1,862 | 14,856 | Form |
| 23 | Jackson, Deborah C | Husband | Sell | 12222025 | 4.71 | 612 | Form | |||
| 24 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 12032025 | 4.06 | 113 | 458 | 13,986 | Form |
| 25 | Gotlib, Phyllis | President, International | Direct | Sell | 12032025 | 4.06 | 3,574 | 14,501 | 501,389 | Form |
| 26 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 10032025 | 6.11 | 332 | 2,027 | 21,739 | Form |
| 27 | Gotlib, Phyllis | President, International | Direct | Sell | 10032025 | 6.11 | 4,959 | 30,282 | 776,435 | Form |
| 28 | Jackson, Deborah C | Direct | Sell | 9172025 | 6.56 | 4,531 | 29,745 | 256,890 | Form | |
| 29 | Zamansky, Dmitry | Chief Product & Tech. Officer | Direct | Sell | 9042025 | 6.77 | 25,605 | 173,407 | 1,338,978 | Form |
| 30 | Jackson, Deborah C | Direct | Sell | 9042025 | 6.79 | 4,531 | 30,759 | 296,411 | Form | |
| 31 | Gotlib, Phyllis | President, International | Direct | Sell | 9042025 | 6.78 | 4,781 | 32,422 | 895,904 | Form |
| 32 | McNeice, Paul Francis | Chief Accounting Officer | Direct | Sell | 9042025 | 6.78 | 113 | 766 | 26,394 | Form |
Investor Activity (13F)
Updated Sep 20, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.